Toyooka Shinichi, Kiura Katsuyuki, Takemoto Mitsuhiro, Oto Takahiro, Takigawa Nagio, Fujiwara Toshiyoshi, Miyoshi Shinichiro, Date Hiroshi
Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
Interact Cardiovasc Thorac Surg. 2012 May;14(5):565-9. doi: 10.1093/icvts/ivs028. Epub 2012 Feb 20.
The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. Between January 2000 and July 2006, 22 consecutive NSCLC patients with pathologically proven mediastinal nodal metastasis were treated with tri-modality therapy. The regimen consisted of docetaxel and cisplatin plus concurrent radiation at a dose of 40-46 Gy. The induction therapy was followed by surgery 4-6 weeks later. The pulmonary resections were composed of a lobectomy in 19 patients, including 3 with a sleeve lobectomy, a bilobectomy in 2 patients and a left pneumonectomy in 1 patient. With a median follow-up duration of 8.7 years, the 3-year and 7-year overall survival (OS) rates for the entire population were 72.7 and 63.6%, respectively. Our results suggest that tri-modality therapy is promising for NSCLC patients with mediastinal nodal metastasis.
本研究的目的是展示多西他赛和顺铂同步放疗后手术治疗非小细胞肺癌(NSCLC)纵隔淋巴结转移的长期疗效。2000年1月至2006年7月,连续22例经病理证实纵隔淋巴结转移的NSCLC患者接受了三联疗法。治疗方案包括多西他赛和顺铂加40-46 Gy的同步放疗。诱导治疗4-6周后进行手术。肺切除术包括19例肺叶切除术,其中3例为袖状肺叶切除术,2例为双叶切除术,1例为左全肺切除术。中位随访时间为8.7年,整个人群的3年和7年总生存率(OS)分别为72.7%和63.6%。我们的结果表明,三联疗法对NSCLC纵隔淋巴结转移患者具有前景。